Cataract lens under the microscope: does it stay put?
NCT ID NCT07099079
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Researchers are studying how stable the RayOne RAO800S intraocular lens is after cataract surgery. The lens replaces the eye's cloudy natural lens and has marks to help surgeons position it. Adults scheduled for cataract surgery in both eyes receive the lens as part of routine care. Eye images taken at follow-up visits track whether the lens rotates over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RayOne RAO800S intraocular lens
- What this could lead to
- If the lens holds its position well, surgeons could have more confidence in using it during routine cataract surgery.
- What could go wrong
- This is a post-market follow-up study, not a test of whether the lens works. It may show that the lens rotates more than expected, and results from 92 people may not reflect everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 92 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients aged 22 years or older who are scheduled for bilateral cataract surgery as part of routine clinical care and are in accordance with the study's inclusion and exclusion criteria.
- Ages
-
22 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligible subjects must meet all the following inclusion criteria in both eyes. 1. Male or female, 22 years or older at the pre-operative visit who have cataract in both eyes and who are eligible for phacoemulsification cataract surgery 2. Subjects who are projected to have best corrected distance visual acuity 0.20 logMAR (20/30) or better in both eyes after IOL implantation by investigator estimation 3. Clear intraocular media other than cataract 4. Contact lens wearers must demonstrate stability of biometry in both eyes 5. Have the capability to understand and sign an EC approved informed consent form and privacy authorization in accordance with local regulations 6. Female subjects must be 1-year postmenopausal, surgically sterilized, or if childbearing potential must use a stabilized and acceptable form of contraception from the beginning throughout the end of the study. Stabilized and acceptable contraception methods include at least one of the following: intrauterine (intrauterine device) or hormonal (oral, injection, patch, implant, ring) for at least 3 months, barrier with spermicide (condom, diaphragm), or abstinence. 7. Have pre-existing corneal astigmatism not exceeding 1.25 D in both eyes as determined by keratometry 8. Dilated pupil size 5.5 mm or greater to allow visualization of the IOL orientation marks post-operatively in both eyes Eligible subjects must not meet any of the following exclusion criteria. Subjects may not participate if either eye meets any of the ocular exclusion criteria: 1. Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK / LASEK / PRK, SMILE, astigmatic keratotomy and limbal relaxing incisions in any eye 2. Diagnosed degenerative visual disorders (e.g. macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) that are predicted to cause future acuity losses to a level of 0.20 logMAR (20/30) or worse 3. Significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g. pseudoexfoliation syndrome, any iris pathology) 4. Subjects with conditions associated with increased risk of zonular rupture (that may affect post-operative centration or tilt of IOL) in any eye 5. Potentially occludable angle or ciliary body tumor, or other pathology that might increase risk to subject safety, based on adequate diagnostics e.g. gonioscopic, anterior OCT observation 6. Subjects reasonably expected to require secondary ocular surgical intervention or laser treatment (other than YAG capsulotomy) 7. Subjects with clinically significant corneal pathology, potentially affecting corneal topography 8. Subjects with traumatic cataract in any eye 9. Currently participating in a drug or device clinical trial, or having participated in such a trial within 30 days prior to the pre-operative visit 10. Subjects with any other serious ocular pathology (e.g. severe dry eye, history of intraocular inflammation, history of retinal surgery or retinal laser procedure) or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study 11. Clinically significant, uncontrolled glaucoma with expected negative impact on IOL Rotational Stability and / or visual acuity outcomes in one or both eyes 12. Use of medications known to interfere with visual performance, pupil dilation, or iris structure within 30 days of the pre-operative visit, at the discretion of the investigator 13. Pregnant or nursing females 14. Pre-operative corneal astigmatism above 1.25D as determined by keratometry 15. Irregular astigmatism in any eye Additional Exclusion Criteria at the Time of Surgery: Subjects who do not meet exclusion criteria described in section 6.2 and are enrolled in the study may present findings during surgery that preclude inclusion of performance data in the investigation and thus need to be excluded from data collection post operatively. The following general exclusion criteria shall be considered during surgery for either eye: 16. zonular instability; 17. need for iris manipulation; 18. capsular fibrosis or other opacity; 19. inability to fixate IOL in desired position If the IOL has touched the eye, it should be noted if the reason for exclusion is related to the IOL itself and/or any (e.g. IOL or insertion device defect causing capsular damage, malfunction of insertion device). If the IOL has touched the eye, the subject should be followed, for safety, until completion of the investigation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Iol, cataract are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.